MGTA News and Press, Magenta Therapeutics Inc. From 05/06/21

Magenta Therapeutics (MGTA): Q1 GAAP EPS of -$0.36 beats by $0.04.Cash, cash equivalents and marketable securities of $132.29M.Press Release For further details see: Magenta Therapeutics EPS beats by $0.04

– Two Phase 2 clinical trials underway to evaluate MGTA-145 plus plerixafor; initial mobilization, collection, engraftment and disease outcome data in Multiple Myeloma patients to be first presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held ...

Clinical-stage biotechnology company Magenta Therapeutic (MGTA) announces the appointment of industry veteran David Nichols as the company's Chief Technical Officer.Nichols comes to Magenta with more than 25 years of experience in biologics process developme...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of David Nichols as Chief Technical Officer. “We are so please...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to p...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availability of data presentations across its stem cell mobilization and targeted conditionin...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to present at the Oppenheimer 31 st Annual Healthcare C...

Magenta Therapeutics (MGTA): GAAP EPS of -$0.38 beats by $0.02.Cash, cash equivalents and marketable securities of $148.8MPress Release For further details see: Magenta Therapeutics EPS beats by $0.02

-- Magenta’s stem cell mobilization and targeted antibody-drug conjugate conditioning programs continue to advance, with four clinical trials ongoing or planned in 2021 – -- Ended year with approximately $148.8 million in cash, cash equivalents and marketable sec...

For patients with certain blood cancers, a stem cell transplant can often be a curative treatment. However, it is also a complex process riddled with severe toxicities and high rates of relapse or failure. These issues are at least part of the reason why only about 60% of cancer patients, a...